OPB-201 for advanced ovarian or endometrial cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, OPB-201, for people with endometrial or ovarian cancer that came back after treatment. It is for those whose cancer has a specific marker called PRAME and a certain HLA type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have a confirmed diagnosis of endometrial, ovarian, peritoneal, or fallopian tube cancer.
- You have had at least one previous chemotherapy that included a platinum drug.
- If you have a BRCA1/2 gene mutation, you have already tried a PARP inhibitor.
- Your cancer can be measured by scans or tests, and you can provide a past tumor sample.
- You are generally up and active (ECOG 0 or 1), and have acceptable organ function.
- Your blood test shows you have the HLA-A*02:01 or *02:02 type, and your tumor is PRAME positive.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Endometrial Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.